Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Especificación
Tipo de cuenta
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Comisiones
0.1%
Horario de operaciones (UTC)
Abrir ahoraCerradoCierre elApertura el
a las
-
El horario de apertura del mercado se indica según su zona horaria local
(UTC)
Abre una cuenta y comienza a invertir con Metadoro ahora. Invite a amigos y obtenga remuneración por su comercio activo. Puede obtener más información sobre el programa de afiliados en su Área Personal.
Gracias por visitarnos metadoro.com. Este sitio web es administrado por RHC Investments, que está autorizada y regulada como Agente de Inversiones por la Comisión de Servicios Financieros de Mauricio con el número de licencia C115015381. Mauricio no forma parte del marco regulatorio europeo y no está dentro del alcance (entre otros) de la Directiva sobre Mercados de Instrumentos Financieros (MiFID) II.
Al continuar, confirma que la decisión se toma de forma independiente y por iniciativa propia y exclusiva y que RHC Investments no ha realizado ninguna solicitud o recomendación.
¡Personalice la suscripción a su manera!Create a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Detección oportuna de altibajos del mercado, fluctuaciones, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found